



CLINICAL INSIGHTS
EPIC™ MITRAL
STENTED TISSUE VALVE WITH LINX AC TECHNOLOGY



Long-Term Outcomes and Freedom from Calcification

INTRODUCTION

The Quebec Heart and Lung Institute at Laval University has a long history with surgical mitral valve replacement (SMVR) with bioprosthetic heart valves¹. Therefore, a study was conducted to evaluate the long-term clinical and echocardiographic outcomes of the Epic™ Mitral stented tissue valve with Linx™ Anti-Calcification technology.

Pre-clinical animal studies demonstrate that Linx™ Anti-Calcification Technology reduces tissue calcification in four ways²⁻⁵:

- Reduces free aldehydes
- Extracts lipids
- Minimizes uptake of cholesterol
- Stabilizes leaflet collagen

STUDY METHOD

- Retrospective design using a prospective single-center registry
- Between 2007 and 2021, n=1,397 consecutive adult patients underwent MVR with the Epic Mitral
 - Exclusion: adult congenital heart disease
- Valve hemodynamics and Structural Valve Deterioration (SVD) were evaluated
- Chart review was performed to identify the mechanism of bioprosthetic failure
- Cox regression analysis was performed to identify the independent risk factors of late mortality and prosthetic mitral valve reoperation
- Follow-up was 100% complete up to maximum 13.6 years post initial MVR

DEMOGRAPHICS

- n=1,397
- Average patient age at implant was 72 years
- 46% female
- Concomitant CABG was performed in 46% of cases and concomitant valve surgery was performed in 46% of cases.


FINDINGS

A key finding from this study was that at 10 years post implant the **freedom from mitral valve reintervention due to SVD was 92.4% and the freedom from all-cause reintervention was 88.9%**. This finding is comparable to the 91.4% freedom from all-cause Epic Mitral valve reintervention at 10 years post-implant in an all-comer real-world population in the USA⁶.

A recent study showed that valves that fail with calcification tend to result in a higher stroke rate after reintervention⁷. The Quebec Heart and Lung Institute experience shows no cases of leaflet calcification (100% freedom from calcification) at the ten year timepoint. The primary mechanism of SVD was regurgitation related to leaflet tear. Epic Mitral with Linx Anti-Calcification Technology’s leaflets are engineered to allow for the lowest leaflet profile and prevent calcification, which may provide a stroke risk advantage in Valve-in-Valve cases*.

CONCLUSIONS

The Quebec Heart and Lung Institute study of the Epic Mitral valve once again confirms excellent long-term durability of the valve with a 92.4% freedom from reintervention due to SVD at 10 years post implant, as well as 88.9% freedom from all-cause reintervention. These long-term study results remain consistent with prior published data⁶. The study showed 100% freedom from calcification, which is in line with literature demonstrating less calcification in porcine valves⁷. Less leaflet calcification in porcine valves may offer an advantage at the time of valve reintervention against stroke risk.



*Note: The safety and effectiveness of valve-in-valve procedures in an Epic™ or Epic™ Supra valve have not been established.

See Important Safety Information referenced within.

Epic™/Epic™ Supra Stented Porcine Tissue Valves Rx Only

Important Safety Information

INDICATIONS FOR USE

The Epic valve is indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic and/or mitral heart valve. It may also be used as a replacement for a previously implanted aortic and/or mitral prosthetic heart valve.

The Epic Supra valve is indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic heart valve. It may also be used as a replacement for a previously implanted aortic prosthetic heart valve.

CONTRAINDICATIONS

None known.

POTENTIAL ADVERSE EVENTS

Adverse events potentially associated with the use of bioprosthetic heart valves (in alphabetical order) include: angina; cardiac arrhythmias; endocarditis; heart failure; hemolysis; hemolytic anemia; hemorrhage, anticoagulant/antiplatelet-related; leak, transvalvular or paravalvular; myocardial infarction; nonstructural dysfunction (entrapment by pannus or suture, inappropriate sizing or positioning, or other); prosthesis regurgitation; stroke; structural deterioration (calcification, leaflet tear, or other); thromboembolism; valve thrombosis.

It is possible that these complications could lead to: reoperation; explantation; permanent disability; death.

REFERENCES

1. Bernard, J. et al. (2023, May). Mechanisms of Failure of a Mitral Valve Porcine Xenograft Prosthesis and Comparison of Outcomes According to Reintervention Approach. Poster presented at the AATS Mitral Conclave, New York.
2. Vyavahare, N, Hirsch, D, Lerner, E, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation. *Circulation*. 1997;95:479-488. doi.org/10.1161/01.CIR.95.2.479.
3. Kelly SJ, Ogle MF, Carlyle WC, et al. Biocompatibility and calcification of bioprosthetic heart valves. Presented at: Society for Biomaterials, Sixth World Biomaterials Congress Transaction. May 2000:1353.
4. Frater RWM, Seifert E, Liao K, et al. Chapter 8. In: Gabbay, S, Wheatley DJ, eds. *Advances in Anticalcific and Antidegenerative Treatment of Heart Valve Bioprostheses*. 1st ed. Silent Partners, Inc; 1997:105-113.
5. Vyavahare NR, Hirsch D, Lerner E, et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. *J Biomed Mater Res*. 1998;40:577-585.
6. Rodriguez, E. et al. (2022, January). Ten-Year Outcomes of a Contemporary Generation Low-Profile Porcine Mitral Bioprosthesis in a Medicare Population. Poster presented at the STS Annual Meeting, Virtual.
7. Melanie Keshishi, Rubab Fatima, Michael A. Seidman, Jagdish Butany, Maral Ouzounian, Jennifer Chung, Comparison of Modes of Failure and Clinical Outcomes Between Explanted Porcine and Bovine Pericardial Bioprosthetic Valves, *Cardiovascular Pathology* (2023), doi:https://doi.org/10.1016/j.carpath.2022.107516

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.
Photo on file at Abbott.

Abbott

3200 Lakeside Dr., Santa Clara, CA 95054 USA, Tel: 1.800.227.9902

™ Indicates a trademark of the Abbott group of companies.

‡ Indicates a third-party trademark, which is property of its respective owner.

www.structuralheart.abbott

© 2023 Abbott. All rights reserved.

MAT-2304595 v1.0 | Item approved for U.S. use only.

